Medpace Holdings, Inc. (MEDP) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 42/100
- 10Y CAGR
- 21.6%
- Median YoY
- 20.1%
- YoY volatility
- σ 16.4pp· uneven
- Quarters ≥ 20%
- 20 of 40
- Negative quarters
- 1
- Valuation vs own 10Y history
- P/S 6.3x · 10Y median 4.5x · 83rd percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 20 of 40 → 20 of 40 pts
- Steadiness (typical swing 16.4pp) → 13.3 of 25 pts
- Pace (median 20.1% YoY) → 6.8 of 20 pts
- Latest quarter (17.2% YoY) → 1.6 of 15 pts
- Score: 42 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 21.6% | 20.1% | 16.4pp | 20 of 40 | 1 |
| EPSEPS | — | 41.7% | 788.0pp | 30 of 38 | 2 |
| Op cash flowOperating cash flow | 23.6% | 22.5% | 53.6pp | 23 of 39 | 9 |
| EBITDAEBITDA | 20.1% | 20.6% | 19.8pp | 21 of 40 | 5 |
| FCFFree cash flow | 24% | 25.7% | 72.0pp | 23 of 39 | 10 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: MEDP on the compounders surface · All compounders, ranked